Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $325.04M
Founded date: 2015
Investors 8
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.04.2024 | Series C | $160.5M | - |
| 09.09.2021 | Series B | $115.04M | - |
| 06.12.2017 | Series A | $49.5M | - |
Mentions in press and media 22
| Date | Title | Description |
| 03.06.2025 | Dimension Bio Appoints Biotech Veteran Heidi Hagen to Board of Directors | Heidi Hagen Dimension Bio appoints biotechnology veteran Heidi Hagen to its Board of Directors, bringing decades of cell therapy leadership as the company advances its liver failure program toward the clinic. CHICAGO, June 3, 2025 /PRNewswi... |
| 01.11.2024 | The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39th Annual Meeting | SITC 2024 Logo The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstr... |
| 20.04.2024 | The Melanoma Research Foundation to host the New England Miles for Melanoma 5K | New England Miles for Melanoma The Melanoma Research Foundation (MRF) is thrilled to announce one of the first events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, care partners and thriv... |
| 08.04.2024 | Obsidian Therapeutics Secures $160.5M in Series C Funding | Obsidian Therapeutics, a cutting-edge biotech company based in Cambridge, MA, has successfully raised a whopping $160.5 million in Series C funding. The round was spearheaded by Wellington Management, with a slew of new investors jumping on... |
| 03.04.2024 | Obsidian Therapeutics Raises $160.5M in Series C Funding | Obsidian Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $160.5M in Series C funding. The round was led by Wellington Management. Additional new investors including Foresite Capital, Janus Henderson Investor... |
| 21.02.2024 | A watershed moment for cancer therapies has arrived | A new class of cancer treatments that harness the body's immune system to fight tumors is being hailed as the biggest thing in oncology since CAR-T revealed the promise of cell therapy more than a decade ago. But with price tags of hundreds... |
| 10.12.2021 | Flagship on center stage: Axcella’s new CMO likens the biotech to ‘professional sports team’; Life after the FDA takes shape for Stephen Hahn as a chief executive | Margaret Koziel Margaret Koziel has bounced back and forth between academia and biotech throughout her career — and after 25 years, she has landed her first position as part of a biotech’s top brass. Koziel joined Axcella Ther... |
| 10.09.2021 | The question that defines venture capital firm Benchmark | For Benchmark, I imagine they take the question with a hint of exasperation, like late stage companies being queried “when will you IPO” the moment they reach unicorn status. Paid Content Optimizely's CEO on upgrading the marketer experienc... |
| 10.09.2021 | The question that defines venture capital firm Benchmark | For Benchmark, I imagine they take the question with a hint of exasperation, like late stage companies being queried “when will you IPO” the moment they reach unicorn status. Paid Content How a global community of chief executives is buildi... |
| 09.09.2021 | Obsidian Therapeutics Announces Closing of $115 Million Series B Financing |
Show more